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Introduction : We hypothesized that radiation-induced thoracic 
toxicity (RITT) of the lung, esophagus and pericardium share 
a similar mechanism, and aimed to examine whether genetic 
variation of transforming growth factor–beta1 (TGFβ1), tis-
sue plasminogen activator (tPA) and angiotensin converting 
enzyme (ACE), are associated with RITT in patients with 
non–small-cell lung cancer (NSCLC).
Methods: Patients with stage I–III NSCLC were enrolled and 
received radiotherapy (RT). Blood samples were obtained pre-
RT and at 4 to 5 weeks during RT, and plasma TGF-β1 was 
measured using an enzyme-linked immunosorbent assay. The 
DNA samples extracted from blood pre-RT were analyzed for 
the following frequent genetic variations: TGFβ1 509C/T, tPA 
-7351 C/T, and ACE I/D. RITT score was defined as the sum 
of radiation-induced toxicity grades in esophagus, lung, and 
pericardium.
Results: Seventy-six NSCLC patients receiving definitive RT 
were enrolled. Patients with TGFß1 509CC had higher mean 
grade of esophagitis (1.4 ± 0.2 versus 0.8 ± 0.2, p = 0.019) 
and RITT score (2.6 ± 0.3 versus 1.6 ± 0.3, p = 0.009) than 
T allele carriers. Although no significant relationship was 
observed between RITT and the tPA or ACE variants individ-
ually, patients with any high-risk alleles (tPA CC or ACE D 
or TGFß1 509CC) had significantly higher grade of develop-
ing combined RITT (p < 0.001). Patients with TGFß1 509CC 
had greater increase of plasma TGF ß1 levels at 4 to 5 weeks 
during RT than T allele carriers did (CC 1.2 ± 0.2 versus T 
0.7 ± 0.1, p = 0.047).
Conclusion: This exploratory study demonstrated that sen-
sitivity of radiation toxicity may be determined by genomic 
factors associated with TGFβ1 and genes involved in TGFβ1 
pathway.
Key Words: Single nucleotide polymorphism, Toxicity, Radiotherapy, 
Non–small-cell lung cancer.
(J Thorac Oncol. 2013;8: 208–213)
Radiation is the mainstay local treatment for patients with inoperable stage I–III non–small-cell lung cancer 
(NSCLC), and an adequate dose is essential for treatment 
success as increased radiation dose has been associated with 
reduction in risk of death.1 However, the majority of patients 
with stage III NSCLC cannot receive an adequate dose for 
tumor control without exceeding the safe dose limits of the 
adjacent critical structures such as lung, esophagus, and heart. 
There are no reliable biologic markers to predict the risk of 
radiation-induced toxicity. Radiation doses during our stan-
dard practice are uniformly limited by the sensitive patient’s 
tolerance. Despite this conservative approach, some patients 
develop severe toxicity, whereas the majority do not, suggest-
ing that genetic makeup may play a critical role in an individ-
ual’s response to radiotherapy (RT) and toxicity development.2
Previous studies on radiation toxicity have been 
largely limited to specific organ toxicity; however, the 
biological mechanism of radiation toxicity in various organs 
at risk is likely to be similar. For example, inflammation is 
seen in esophagitis, pneumonitis and pericarditis. Genetic 
variations that lead to functional differences in proteins that 
participate in inflammatory processes may contribute to 
individual susceptibility to radiation-induced thoracic toxicity 
(RITT) including esophagitis, pneumonitis, pericarditis and 
pericardial effusion in patients with NSCLC.
Transforming growth factor–beta1 (TGF-β1) plays 
a crucial role in radiation-induced inflammation.3 Tissue 
plasminogen activator (tPA) has been shown to participate 
in TGFβ1 activation, the regulation of inflammation, and 
the modulation of radiation-induced toxicity.4,5 In addition, 
angiotensin-converting enzyme (ACE) and its inhibitors may 
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mitigate radiation-induced lung injury,6,7 possibly through the 
TGF-β1 pathway.
We hypothesized that the genetic variation of TGFβ1, 
tPA, and ACE are associated with accumulated overall RITT 
involving inflammation of lung, esophagus, and pericardium. 
We specifically selected the single nucleotide polymorphisms 
(SNPs), TGFβ1 509C/T, and tPA-7351 C/T, and the insertion 
(I)/deletion (D) polymorphism of ACE based on four crite-
ria: (1) A minor allele frequency of at least 20% (~36% for 
rs1800469 TGFβ1 509C/T, 28% for rs2020918 tPA-7351 
C/T, and 46% for rs4646994 I/D polymorphism of ACE; 
(2) Functional location such as in the promoter untranslated 
region or coding region of the gene; (3) Reported association 
between the variant and its protein level; (4) Reported asso-
ciation with radiation injury induced inflammation or fibrosis.
MATERIALS AND METHODS
Study Population
The study population included the patients enrolled in 
Institutional Review Board approved prospective imaging and 
biomarker studies between 2003 and 2009 at our institutes. 
Written informed consent was obtained from each patient. 
Eligible subjects included patients with stages I–III NSCLC 
undergoing radiation alone or combined radiation and chemo-
therapy. Exclusion criteria included a life expectancy of less 
than 6 months, biopsy-proven supraclavicular lymphadenopa-
thy, malignant pleural or pericardial effusion, or noncontigu-
ous involvement of the parietal pleura. All radiation was given 
using three-dimensional conformal techniques, as previously 
described.8,9 Radiation dose was prescribed in majority of 
cases to a rate of 15 to 17% of lung normal tissue complica-
tion in our treatment studies, limited by 15% of normal tis-
sue complication probability in imaging studies per standard 
care. Patients were seen weekly during RT, and then 1, 3, 6, 12, 
and 24 months after RT and assessed for RITT. The minimum 
follow-up duration was 12 months for surviving patients. The 
RITT score was defined as the sum of radiation-induced esoph-
agus, lung, and pericardium toxicity grades. Radiation-induced 
lung toxicity (RILT) included pneumonitis and fibrosis, radia-
tion-induced esophageal toxicity included dysphagia and ody-
nophagia, and radiation-induced pericardium toxicity included 
pericardial effusion and pericarditis. All toxicities were graded 
prospectively per Common Terminology Criteria for Adverse 
Events version 3.0 (CTCAE3.0 http://ctep.cancer.gov/proto-
colDevelopment/electronic_applications/docs/ctcaev3.pdf)
Sample Preparation and Plasma 
TGF-β1 Measurement
Blood samples were collected with Vacutainer Plus col-
lection tubes (Becton, Dickinson and Co., Franklin Lakes, NJ) 
containing anticoagulant (dikalium salt of ethylenediaminetet-
raacetic acid [K2EDTA]) then placed in ice immediately after 
collection, and centrifuged within 3 hours of collection at 3000 
g for 30 minute at 4°C. Plasma TGFβ1 levels were measured 
at baseline (within 2 weeks before RT start), and 4 to 5 weeks 
during RT. Plasma TGFβ1 levels were measured using a TGFβ1 
specific Enzyme-Linked Immunosorbant Assay (Human 
TGFβ1 DuoSet kit, R&D Systems Inc., Minneapolis, MN).
Genotypes
The buffy coat was collected and stored at −80°C. The 
genomic analyses were performed on the DNA isolated from 
the buffy coat drawn from NSCLC patients within 2 weeks 
before RT start.
Genomic DNA was extracted from the buffy coat samples 
with a DNA Blood Mini Kit (Qiagen, Valencia, CA) according 
to the manufacturer’s instructions. Polymerase chain reaction 
(PCR) and sequencing primers for the SNPs of TGFβ1 509C/T, 
and tPA-7351 C/T were designed using Pyrosequencing 
Primer Design Version1.0 software. PCR reactions were car-
ried out in a 30-µl volume with 1.5 mmol/l Mg2+, 10 pmol of 
forward primer, and 10 pmol of reverse primer according to the 
following specifications: initial denaturation time of 5 minutes 
at 95°C followed by 45 cycles of 95°C for 30 seconds, 43°C 
for 30 seconds, 72°C for 30 seconds, and a final extension of 
10 minutes at 72°C. Genotyping of TGFβ1 509C/T, and tPA-
7351 C/T was carried out with Pyrosequencing Technology.10 
The I/D polymorphisms of ACE were examined by electropho-
resis on 1.8% agarose gels stained with ethidium bromide after 
PCR. Specific assay conditions are available upon request.
Statistical Analysis
The relationship between the various SNPs and toxic-
ity was assessed in numerous ways. In the primary analyses, 
genotype was treated as a binary covariate (CC versus T allele 
carrier for TGFβ1 and tPA, and I versus D allele carriers for 
ACE). The Cochrane-Armitage trend test was used to assess 
whether patients with one genotype tended to have higher (or 
lower) toxicity grades than patients with other genotypes did. 
Separate analyses were performed in which genotype was 
treated as categorical and ordinal. Other analyses were based 
on RITT and on definition of sensitive patients as those with 
any of three sensitive genotypes. However, given the explor-
atory nature of this work, no adjustments for multiplicity were 
made. All tests were two-sided and a p value less than 0.05 
was considered statistically significant. Data are presented 
as mean+standard error of mean. The software package SAS 
(V9.2, Cary, North Carolina) was used for analysis.
RESULTS
Patient and Genotypes
From 2003 to 2009, 76 patients with stages I–III NSCLC 
requiring radiation-based therapy were enrolled in the study. 
All NSCLC patients received RT (a median dose of 66 Gy) 
and 56 of them (74%) underwent platinum-based concurrent 
chemotherapy. Among the patients with chemotherapy, 73% (41 
of 56) received pacitaxol + carboplatin, 14% (8 of 56) received 
cisplatin and etoposide, and the remaining patients received 
other chemotherapy regimens. No significant differences 
in mean toxicity scores were found in lung (0.7 ± 0.1 versus 
0.5 ± 0.3 versus 0.6 ± 0.3, p = 0.884), esophagus (1.0 ± 0.2 
versus 1.3 ± 0.6 versus 1.6 ± 0.3, p = 0.435), pericardium 
(0.4 ± 0.1 versus 0.1 ± 0.1 versus 0.9 ± 0.1, p = 0.059) and 
combined RITT (2.1 ± 0.3 versus 1.9 ± 0.7 versus 3.0 ± 0.8, p = 
0.381) among patients with pacitaxol + carboplatin, cisplatin + 
etoposide, and other chemo regimens.
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Patient-, disease-, and treatment-related characteristics 
according to the genetic variations are shown in Table 1. There 
were no significant differences between the genomic groups 
in age, sex, performance status, history of cardiovascular dis-
ease, chronic obstructive pulmonary disease, tumor histol-
ogy, disease stage, receipt of chemotherapy versus RT only, 
and radiation dose received (p > 0.05 for all); the only differ-
ence noted was in the distribution of tPA-7351 C/T genotype 
among the different tobacco use groups (p = 0.02).
Genotype and Thoracic Toxicity
The distribution of various grades of toxicity is shown 
in Figure 1. Patients with the TGFß1 CC genotype had 
higher grade of esophagitis than T allele carrier patients (CC 
1.4 ± 0.2 versus T allele carriers 0.8 ± 0.2, p = 0.019). There 
was no significant difference in mean toxicity grade of lung 
(CC 0.8 ± 0.2 versus T allele carriers 0.5 ± 0.1, p = 0.179), and 
pericardium (CC 0.4 ± 0.1 versus T allele carriers 0.3 ± 0.1, 
p = 0.42), although those with the CC genotype had higher 
grade toxicities than T allele carriers. TGFß1 CC patients 
had significantly greater mean scores for all RITT than T 
allele carriers (CC 2.6 ± 0.3 versus T allele carriers 1.6 ± 0.3, 
p = 0.009) (Fig. 2). No significant difference was observed in 
any individual RITT or mean grade of RITT either between 





TFGβ1 509C/T tPA-7351 C/T ACE I/D
CC CT TT CC CT TT II ID DD
Age, years p = 0.818 p = 0.176 p = 0.626
43.4–68.0 (n = 38) 20 18 0 13 23 2 15 16 7
68.0–86.5 (n = 38) 22 16 0 19 15 4 19 14 5
Sex p = 0.546 p = 0.919 p = 0.114
Male (n = 61) 34 27 0 25 31 5 28 26 7
Female (n = 15) 8 7 0 7 7 1 5 5 5
KPS p = 0.072 p = 0.649 p = 0.650
≤ 80 (n = 36) 16 20 0 17 16 3 14 17 5
> 80 (n = 40) 26 14 0 15 22 3 19 14 7
Weight loss p = 0.929 p = 0.960 p = 0.077
< 5 lb(n = 60) 33 27 0 25 30 5 30 22 8
≥ 5 lb( n = 16) 9 7 0 7 8 1 3 9 4
Smoker p = 0.617 p = 0.022 p = 0.217
Yes (n = 63) 34 29 0 23 36 4 30 26 7
No (n = 13) 8 5 0 9 2 2 3 7 3
COPD p = 0.836 p = 0.615 p = 0.066
Yes (n = 32) 22 17 0 17 20 2 21 15 3
No (n = 44) 20 17 0 19 15 3 12 16 9
CVD p = 0.161 p = 0.121 p = 0.369
Yes (n = 32) 21 11 0 13 16 3 16 13 3
 No (n = 44) 21 23 0 19 22 3 17 18 9
Histology p = 0.565 p = 0.656 p = 0.646
Adenocarcinoma (n = 12) 7 5 4 7 1 6 4 2
Squamous arcinoma (n = 42) 14 8 0 12 8 2 12 7 3
Not otherwise specified (n = 42) 21 21 0 16 23 3 15 20 7
Clinical stage p = 0.936 p = 0.489 p = 0.584
I, II (n = 22) 12 10 0 9 10 3 10 10 2
III (n = 54) 30 24 0 23 28 3 23 21 10
Chemotherapy p = 0.282 p = 0.225 p = 0.437
Yes (n = 56) 33 23 0 21 31 4 24 23 12
No (n = 20) 9 11 0 12 7 2 11 7 2
RT dose p = 0.645 p = 0.657 p = 0.150
≤ 66 Gy (n = 38) 20 18 0 18 20 2 19 16 3
> 66 Gy (n = 38) 22 16 0 16 18 4 14 15 9
KPS, Karnofsky performance score; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; RT, radiotherapy.
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Considering TGFβ1 CC, tPA CC, and ACE D allele car-
riers as sensitive genotypes, nine patients without these sen-
sitive genotypes had significantly lower mean toxicity scores 
of esophagus (0 ± 0 versus 1.3 ± 0.1, p = 0.002), and lung 
(0 ± 0 versus 0.8 ± 0.1, p = 0.021 and all RITT (0.3 ± 0.2 ver-
sus 2.4 ± 0.2, p < 0.001) than those with sensitive genotypes, 
although their pericardium toxicity was not significantly dif-
ferent (0.3 ± 0.2 versus 0.4 ± 0.1, p = 0.787). However, no 
significant differences in mean toxicity scores were found 
in lung, esophagus, pericardium and combined RITT among 
patients with one, two, or three sensitive genotypes (RITT 
score 2.4 ± 0.3 versus 2.3 ± 0.3 versus 2.6 ± 0.7, p = 0.912).
Genotype and Plasma TGF β1
In the entire group of patients, the mean pre-RT TGFß1 
level was 10.7 ± 2.3 ng/ml, and the mean during RT TGFß1 
level was 6.0 ± 0.7 ng/ml. No significant differences in TGFß1 
levels were found at pre-RT and during RT in patients with 
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ACE DD genotype had marginally higher pre-RT TGFß1 lev-
els than patients with the II and ID genotypes did (DD 23.6 ng/
ml versus II 9.0 ng/ml versus ID 7.5 ng/ml, p = 0.05); there was 
no difference during RT (p = 0.346) or in the during-RT/pre-
RT ratio (p = 0.433). However, patients with TGFß1 509CC 
had greater increase in plasma TGF ß1 level at 4 to 5 weeks 
during RT than T allele carriers (TGFß1 ratio of during-RT/
pre-RT were CC 1.2 ± 0.2 versus T allele carriers 0.7 ± 0.1, 
p = 0.047). (Table 2)
DISCUSSION
The data from the current study indicate that genetic vari-
ation of TGFβ1 pathway genes may be associated combined 
RITT in lung, esophagus, and pericardium. TGFβ1 -509 T 
allele carriers had significantly less severe radiation esophagitis 
(p = 0.019) and mean grade of RITT (p = 0.009) than TGFß1 
CC patients. Patients with sensitive genotypes in this pathway 
had significantly higher grade of toxicity in lung, esophagus, 
and RITT than those without sensitive genotypes (p < 0.01)
The finding of the current study on TGFß1 pathway 
genotypes in all RITT has not been reported previously. From 
a biological standpoint, this finding is consistent with previous 
reports of TGFß1 in radiation normal tissue damage11,12 and 
that TGF-β1 levels may influence the pathologic process of 
radiation-induced inflammation and fibrosis.3 Zhao et al.13,14 
and Anscher et al.15 have previously reported that radiation-
induced elevations of plasma TGF-β1 levels during RT is pre-
dictive of RILT. The combination of TGF-β1 and mean lung 
dose may help stratify the patients for their risk of RILT. A 
normal plasma level of TGFβ1 by the end of RT was more 
common in patients without RILT. Changes in plasma TGF-
β1 levels during RT were found to be useful in identifying 
patients at low risk for complications after radiation up to 
86.4 Gy.9 Fu et al.16 reported that an elevated plasma TGFβ1 
level at the end of RT is an independent risk factor for RILT. 
Novakova-Jiresova et al.17 also observed a trend of plasma 
TGFβ1 concentration to decrease below the pretreatment 
value during the RT treatment in patients who did not develop 
pulmonary complications after the RT treatment.
Overall, the literature suggests a potential role of TGFβ1 
in radiation lung damage and the value of using plasma TGFβ1 
to predict RILT. However, measurement of plasma TGFβ1 
is challenging for its reproducibility, as the plasma is easily 
contaminated with platelets. Testing with TGFß1 genotypes 
may accelerate the clinical application of TGFß1 in future 
clinical trial and practice. Genomic analysis is attractive for 
its resistance to variations in methodology of sample hand-
ing, as DNA is very stable. More importantly, risk assessment 
at baseline would provide an opportunity to individualize the 
entire course of treatment whereas assessment midtreatment 
will only guide the remaining treatment.
TGFβ1 SNPs are associated with TGFβ1 plasma level. 
Shah et al.18 reported that the common functional SNPs of 
C-509T have been linked to a nearly twofold difference in 
plasma levels of TGFβ1. In this study, we found that patients 
with TGFß1 509CC had higher elevation of plasma TGF ß1 
level at 4 to 5 weeks during RT than with T allele carriers. 
This may help explain the correlation between TGF ß1 level 
elevation and higher risk of radiation-induced lung toxicity, 
which was reported in our previous publications.13–15 Therefore, 
it has been suggested that the molecular mechanism for the 
risk of radiation-induced lung toxicities may be linked to the 




TFGβ1 509C/T tPA-7351 C/T ACE I/D
CC CT TT p CC CT TT p II ID DD p
Pre-RT (ng/ml) 8.1 ± 1.2 13.8 ± 4.9 — 0.223 8.7 ± 1.4 12.6 ± 4.5 10.3 ± 5.4 0.734 9.0 ± 1.5 7.5 ± 1.1   23.6 ± 13.6 0.050
During- RT (ng/ml) 6.6 ± 1.0  5.3 ± 0.9 — 0.333 5.5 ± 0.8  6.4 ± 1.0 7.0 ± 4.0 0.768 7.2 ± 1.2 5.2 ± 0.9  4.9 ± 1.2 0.346
Ratio 1.2 ± 0.2  0.7 ± 0.1 — 0.047 1.3 ± 0.3  1.1 ± 0.2 0.8 ± 0.1 0.675 1.2 ± 0.2 1.0 ± 0.2  0.7 ± 0.3 0.433
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Yuan et al.2 also reported high risk of radiation pneumonitis 
in patients exhibiting CC in TGF-β1-509C/T. Wang et al.19 
reported that genotype of TGF-β1-509C/T polymorphism was 
associated with the incidence of radiation-induced esophagus 
toxicity. Liu et al.20 reported the pleiotropic effects of TGFβ1 on 
pericardial interstitial cells, implicating its effect for fibrosis and 
calcification in idiopathic constrictive pericarditis. The current 
study may serve as an independent validation of TGF-β1 in 
overall radiation injury in normal tissue. Patients expressing CC 
in TGFβ1-509C/T had significantly higher incidence of RITT 
and esophagitis and nonsignificant but increased toxicity score 
of lung and pericardium. If further validated in studies with 
a larger number of patients in a multicenter setting, TGFβ1-
509C/T may be used as a convenient biomarker to individualize 
radiation therapy in lung cancer.
Considering TGFβ1, tPA, and ACE as parts of a single 
pathway, it can be shown that any functional variant of these 
proteins would change the sensitivity RITT of one individual. 
This was partly supported by the result of the current study in 
which patients without sensitive genetic variants in this pathway 
had significantly lower mean toxicity scores of esophagus 
(p = 0.002), lung (p = 0.021), and combined RITT (p < 0.001) 
than that of patients with any sensitive variant. It seems that one 
functional SNP in the pathway was sufficient to predispose a 
patient at higher risk as there was no significant difference in 
toxicity grade between patients with 1, 2 ,or 3 sensitive variants.
However, we acknowledge that this study is limited by its 
sample size, which may explain why we did not detect a differ-
ence in any RITT either between tPA-7351 CC and T allele car-
riers, or between ACE II and D allele carriers. The insignificant 
result of RITT with genotypes of tPA and ACE may indicate 
that TGFβ1 plays a more important role than either tPA or ACE 
in the complicated signal transduction pathway for radiation-
induced normal tissue injury. Nevertheless, the association of 
the genotypes between TGF-β1 C-509T and grades of RITT 
support our hypothesis that radiation-inflammation–related 
toxicity of different organs may share a similar mechanism.
In summary, results from this hypothesis-driven study 
indicate that functional TGF-β1 genotypes C-509T may play 
an important role in the development of RITT, and future 
radiation toxicity studies may be carried out in patient level 
based on biologic mechanism. The approach of combining all 
RITT may have a greater impact on individualized care, as it 
provides an opportunity to assess the patient as a whole rather 
than organ by organ. Further study with a larger number of 
patients (ideally in a multicenter setting) is needed to validate 
our findings of the genetic variations in accumulative RITT.
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